LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• LifeStance Health Group, Inc. (NASDAQ:LFST) has received an average rating of "Moderate Buy" from nine brokerages, with an average twelve-month price target of $8.50.
• Insider transactions include the sale of 8.4 million shares by Director Darren M. Black and major shareholder Summit Partners L. P. on August 18, resulting in a 20.05% decrease in their ownership.
• LifeStance reported a 10.6% year-over-year increase in quarterly revenue, totaling $345.31 million, and surpassed analysts' earnings expectations for the quarter.

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.

A number of equities analysts have recently commented on the stock. BTIG Research assumed coverage on shares of LifeStance Health Group in a research report on Friday, July 25th. They issued a "buy" rating and a $8.00 price objective for the company. UBS Group lifted their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of LifeStance Health Group in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of LifeStance Health Group from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Finally, Zacks Research upgraded shares of LifeStance Health Group from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 7th.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 8,407,643 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the sale, the director directly owned 33,524,715 shares in the company, valued at $169,970,305.05. The trade was a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the insider directly owned 33,524,715 shares in the company, valued at $169,970,305.05. This trade represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,407,643 shares of company stock worth $103,466,750 over the last three months. 6.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in LFST. Parcion Private Wealth LLC purchased a new position in shares of LifeStance Health Group in the first quarter worth $15,670,000. Bank of America Corp DE increased its stake in shares of LifeStance Health Group by 280.1% in the second quarter. Bank of America Corp DE now owns 1,767,051 shares of the company's stock worth $9,136,000 after buying an additional 1,302,140 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of LifeStance Health Group in the first quarter worth $7,932,000. Qube Research & Technologies Ltd increased its stake in shares of LifeStance Health Group by 90.5% in the second quarter. Qube Research & Technologies Ltd now owns 2,455,027 shares of the company's stock worth $12,692,000 after buying an additional 1,166,045 shares during the period. Finally, Nuveen LLC purchased a new position in shares of LifeStance Health Group in the first quarter worth $6,928,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $5.04 on Monday. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.61. The company has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $5.42. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market capitalization of $1.96 billion, a PE ratio of -100.80 and a beta of 1.17.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $345.31 million during the quarter, compared to analyst estimates of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) earnings per share. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.